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Abstract A distinctive tract of all the forms of Alzheimer’s
disease is the extracellular deposition of a 40^42/43 amino acid-
long peptide derived from the so-called L-amyloid precursor
protein (APP). This is a membrane protein of unknown function,
whose short cytosolic domain has been recently demonstrated to
interact with several proteins. One of these proteins, named
Fe65, has the characteristics of an adaptor protein; in fact, it
possesses three protein-protein interaction domains: a WW
domain and two PID/PTB domains. The interaction with APP
requires the most C-terminal PID/PTB domain, whereas the
WW domain is responsible for the interaction with various
proteins, one of which was demonstrated to be the mammalian
homolog of the Drosophila enabled protein (Mena), which in turn
interacts with the cytoskeleton. The second PID/PTB domain of
Fe65 binds to the CP2/LSF/LBP1 protein, which is an already
known transcription factor. The other proteins interacting with
the cytosolic domain of APP are the Go heterotrimeric protein,
APP-BP1 and X11. The latter interacts with APP through a
PID/PTB domain and possesses two other protein-protein
interaction domains. The small size of the APP cytodomain
and the overlapping of its regions involved in the binding of Fe65
and X11 suggest the existence of competitive mechanisms
regulating the binding of the various ligands to this cytosolic
domain. In this short review the possible functional roles of this
complex protein network and its involvement in the generation of
Alzheimer’s phenotype are discussed.
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1. Introduction
The molecular basis of Alzheimer’s disease (AD) is not fully
understood and many apparently unrelated proteins are prob-
ably involved in the generation of the cellular and molecular
phenotypes of the disease. The distinctive tract of AD at cel-
lular level is represented by the degeneration of speci¢c neuro-
nal populations in the central nervous system. Histological
analysis of a¡ected brains drew the attention of research to
several characteristics of the disease, that include the presence
in the brain of amyloid plaques, neuro¢brillary tangles and
vascular alterations. Amyloid plaques mostly consist of a de-
posit of amyloid ¢bers, whose main constituent is a 40^42
amino acid-long peptide, named L-amyloid peptide (LA).
One possible hypothesis to explain AD pathogenesis is cen-
tered on the neurotoxic e¡ect of LA and/or of amyloid ¢bers
[1,2]. Despite the huge amount of experimental results avail-
able, this hypothesis was not fully demonstrated [3].
An important contribution to the understanding of AD
pathogenesis came from the identi¢cation of the genes whose
mutations are linked with the familial forms of AD (FAD).
Considering that the FAD phenotype is similar to that of AD,
but for the early onset of the disease, it is conceivable that the
functions of the proteins encoded by these three genes could
be altered, and thus are responsible for the sporadic forms of
AD as well. These three genes encode the L-amyloid precursor
protein (APP) [4], presenilin 1 and presenilin 2 (PS1, PS2) [5].
Furthermore, the O4 allele of the apolipoprotein E gene is
associated with an increased risk of late onset AD [6].
The APP gene encodes several di¡erent isoforms of APP as
a consequence of alternative splicing events; all these forms
are membrane proteins with a single transmembrane tract, a
large extracellular/intraluminal (E/IL) domain and a small cy-
tosolic (CY) domain. APP undergoes complex alternative pro-
teolytic processing events, giving rise, in the case of the K-
secretase pathway, to the soluble form of the entire E/IL do-
main and to a C-terminal fragment [7] or, in the case of the
combined action of the L- and Q-secretase pathways to a short-
er soluble form of the E/IL domain, to the LA peptide and to
a shorter C-terminal fragment [8,9]. Again, the functional sig-
ni¢cance of these proteolytic pathways is still unknown, but it
is well demonstrated that they take place in di¡erent intra-
cellular compartments: the K-secretase pathway, which pre-
vents the formation of the LA peptide and thus is not amy-
loidogenic, takes place near or at the plasma membrane [10],
whereas the L-secretase pathway (amyloidogenic) takes place
at endosomal/lysosomal structures [11] and at Golgi-derived
vesicles [12] and/or in the ER/intermediate compartment [13].
The functions of APP and presenilins are poorly (or not)
understood and it is evident that de¢ning these functions
would be greatly relevant for the understanding of the molec-
ular bases of AD. While no ligand has been clearly demon-
strated for the large EC/IL domain of APP, the analysis of its
short CY domain opened a stimulating new research area. In
fact, starting from the observation that the Fe65 protein in-
teracts with the APP cytodomain [14], many research data
have documented the existence of a protein-protein interac-
tion network centered to the APP cytodomain.
2. Structure and expression of Fe65, a new adaptor protein
Fe65 was originally identi¢ed as an EST corresponding to
an mRNA expressed at high levels in the rat brain. The se-
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quence of the full length Fe65 cDNA revealed that it encodes
a protein of 711 amino acids and a ¢rst comparison of this
amino acid sequence with those contained in data banks re-
vealed that a region of Fe65 can be aligned with a region of
the retroviral integrases, DNA binding proteins which cata-
lyse the integration of the proviral DNA into the host genome
[15]. This observation, together with the demonstration that a
short segment of Fe65, £anking at the N-terminal side the
integrase homology, is a strong transcription activator, sug-
gested the hypothesis that Fe65 could function as a transcrip-
tion factor [15]. Following the discovery of two novel protein-
protein interaction domains, the PID/PTB domain [16] and
the WW domain [17], it was suggested that Fe65 has the
characteristics of an adaptor protein, possessing a WW do-
main and two distinct PID/PTB domains. As summarized in
Fig. 1, the WW domain of Fe65 covers the residues from 254
to 290, whereas the two PID/PTB domains, referred to as
PID1 and PID2, are located from residue 365 to 510 and
from residue 538 to 665, respectively.
The WW domain was originally discovered in the protoon-
cogene-Yes-associated protein (YAP) [17], and it mediates the
interaction with proteins containing XPPXY or PPLP consen-
sus motifs [18]. More than 40 proteins have been identi¢ed
which possess one or more WW domains and at least two
types of this motif exist. The Fe65 WW belongs to the type
II group, and it is expected that the similarity among various
WW-containing proteins implies a similarity in the functional
characteristics.
While the WW domain of Fe65 is conserved compared to
those found in other proteins, the Fe65 PID/PTB domains
signi¢cantly diverge from those found in Shc, IRS1 and other
proteins. The alignment of PID1 and PID2 with the PID/PTB
domain of Shc [19] and the data concerning the tridimensional
structure of Shc [20] demonstrated that: (i) the Fe65 PID/PTB
domains are shorter than that of Shc, so that the long K2 helix
of Shc is absent from both PID1 and PID2; (ii) three key
basic residues of Shc, involved in the interaction with the
phosphate moiety of the NPXpY element, cannot be aligned
with any similar residue in the Fe65 domains; (iii) the most
conserved region among the three domains is the C-terminal
part, including the K3 helix of Shc; however, the Phe198 res-
idue of Shc, contained in this region, whose mutation com-
pletely impairs the binding activity of Shc [21], is substituted
in both the Fe65 PID/PTB motifs by a cysteine. In agreement
with these last observations, chimeric proteins, in which the
C-terminal K helix of Shc is substituted with the C-terminal
regions of both the Fe65 PIDs, are unable to interact with
tyrosine phosphorylated receptors [19].
Northern blot analyses demonstrated that the rat Fe65
mRNA is detectable only in the brain [15], and only RNase
protection experiments allowed the detection of low levels of
this mRNA in other tissues. The mouse Fe65 mRNA is also
detectable in other tissues, although these levels are at least
two orders of magnitude lower than in the brain [22]. The
mapping of Fe65 gene expression in the various tissues dem-
onstrates that during the development Fe65 mRNA is re-
stricted, starting from day E10, to speci¢c areas of the nerv-
ous system (NS) of the mouse embryo and it is undetectable in
other tissues [23]. The highest levels of this mRNA are present
in all the ganglial structures of the NS and of the sense organs
and in the cortex, particularly at the level of the hippocampus
[23].
In cultured cells the in vivo observed di¡erences between
neural and non-neural tissues are less evident. In PC12 cells
the Fe65 mRNA and protein levels are signi¢cantly higher
than in other cell lines, but in all the cell types examined
the amount of Fe65 is higher than that observed in the cor-
responding tissues (unpublished results). This discrepancy be-
tween cultured cells and tissues is also evident from the study
of the rat Fe65 gene promoter. In fact, the most proximal of
at least two start sites of the promoter is strong in neural
derived cell lines, but it is still active in non-neural cells [24],
and the transcription factors that bind to and regulate this
promoter are not neural-speci¢c [25]. This probably means
that Fe65 is not restricted to speci¢c areas of the nervous
system, but the levels of its expression are signi¢cantly higher
in these districts compared to other tissues. Furthermore, the
increase of Fe65 expression levels in cultured cells compared
to the cognate tissues suggests the hypothesis that in vitro
growth conditions require higher amounts of Fe65.
3. Interaction of Fe65 with APP and APP-related proteins
By using as a bait the Fe65 region containing the two PID/
PTB domains, the screening of a brain cDNA library in the
yeast two hybrid system allowed to isolate cDNA fragments
encoding the cytodomain of APP and of an APP-related pro-
tein, APLP1 [14]. Based on the opposite approach, i.e. by
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Fig. 1. Schematic representation of the domains of Fe65. The boundary residues of the three domains are reported in the upper part of the ¢g-
ure. In the lower part the representation of the other two members of the Fe65 protein family is reported, with the percentage of similarity of
the domains compared to Fe65. The sequences used for the comparison are derived from the translation of: (i) for Fe65, the rat cDNA (AC:
X60468); (ii) for Fe65L1, the human cDNA (AC: U62325); (iii) for Fe65L2, the rat cDNA (AC: Y13413).
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using the cytodomain of APP as a bait, several research
groups isolated cDNA fragments encoding Fe65 [22,26^28].
As demonstrated by in vitro and in vivo experiments APP
and APP related proteins, APLP1 and APLP2, bind to the
PID2 element of Fe65, whereas the PID1 element is com-
pletely dispensable [19].
Fe65 is an extremely conserved protein: its sequences in
man, mouse and rat show more than 95% identity. It belongs
to a multigene family. In rat and human there are at least
three genes of this family, whose products have been named
Fe65, Fe65L1 and Fe65L2 [26,29]. Fig. 1 shows a schematic
representation of the structure of these three proteins, in
which the three protein-protein interaction domains are sig-
ni¢canly conserved, whereas most of the remaining parts of
the proteins are unrelated. They are functionally very similar;
they in fact interact with APP through the PID2 element, but
also with the other members of the APP protein family. Rat
Fe65 and Fe65L2 interact with high a⁄nity with APLP2 and
APP and to a lesser extent also with APLP1 [29]. Human
Fe65L1 strongly interacts with APP and APLP2, but not
with APLP1 [26]. The most signi¢cant di¡erence among these
proteins seems to be their tissue distribution: Fe65 mRNA is
mostly expressed in the brain, and particularly in neurons of
speci¢c areas of the nervous system, whereas human Fe65L1
mRNA is ubiquitously expressed [26] and rat Fe65L2 mRNA
signi¢cantly accumulates in the brain and in the testis [29].
The analysis of the interaction between Fe65 and the mu-
tant forms of APP isolated from FAD patients demonstrated
that the amount of Fe65-APP/FAD complexes found in cul-
tured cells is signi¢cantly lower than those of Fe65 with wild-
type APP. Particularly in CHO cells stably expressing the so-
called Swedish mutant of APP the levels of the complexes
between Fe65 and this mutant protein are undetectable [19].
4. The APP cytodomain is able to interact with various proteins
The APP cytodomain is able to interact with at least three
other proteins, completely unrelated to Fe65. The ¢rst type of
proteins that was identi¢ed as possible ligand of the APP
cytodomain is represented by Go protein. In fact, there are
some results indicating that the peptide from residue 657 to
residue 676 of APP binds to and activates the Go protein
[30,31]; this interaction mimics those of transmembrane re-
ceptors with trimeric G proteins; in fact, although the natural
signal that uses the APP-Go transduction machinery is not
known, an anti-APP antibody is able to activate Go [32].
The authors also observed that: (i) FAD-mutant APPs con-
stitutively activate Go [33,34]; (ii) FAD mutant APPs induce
apoptosis in COS cells; and (iii) this phenomenon is mediated
by the GLQ subunit of Go [35,36]. If con¢rmed, these results
could be of great relevance to the AD phenotype.
A second protein interacting with the APP cytodomain is
X11 [27]. This is a neuron abundant protein [37], which shares
with Fe65 the characteristic of being a candidate adaptor
protein; in fact, it interacts with APP through a PID/PTB
domain, similar to those found in Fe65, and also possesses
two other protein-protein interaction domains, belonging to
the group of PDZ (PSD-95/Dlg/ZO-1) domains. Furthermore,
as for Fe65, a second X11 protein (X11L) was identi¢ed. Very
interestingly, it was recently demonstrated that transient over-
expression of X11 in cultured cells provokes a decreased se-
cretion of L-amyloid peptide in the medium [38].
Another possible ligand of the APP cytodomain was named
APP-BP1 [39]. Very little information is available on this pro-
tein; its primary structure deduced from the cDNA sequence
indicates that it is similar to the auxin resistance gene product
AXR1 of Arabidopsis and to a protein in Caenorhabditis ele-
gans of unknown function.
5. Possible competition among various proteins for the binding
to the cytodomain of APP
The above described results demonstrated that at least four
types of proteins can interact with the APP cytodomain.
There are several experimental results suggesting that the con-
temporary binding of Fe65 and X11 seems to be impossible
and that of Fe65 and Go is not probable. Although no result
is available concerning the region of APP involved in the
interaction with APP-BP1, given the small size of the APP
cytodomain, the competition between APP-BP1 and the other
ligands of the APP cytodomain is conceivable.
Fig. 2 summarizes the experimental results obtained by us-
ing synthetic peptides or mutant forms of APP, indicating that
the shortest APP peptide, which is still able to interact with
Fe65, is represented by the C-terminal 32 residues [19]. This
region includes the peptide interacting with X11 and signi¢-
cantly overlaps with the putative domain of binding to APP
of Go proteins. Furthermore, at least Tyr652 is not dispensable
for the binding of both Fe65 and X11 [27].
The solution conformation of the APP cytodomain, studied
by NMR and CD spectroscopy, indicated that the most prom-
inent features of this peptide are two type I reverse turns
adopted by the sequences TPEE and NPTY [40]. The NPXpY
motif has been identi¢ed as the recognition site for the PTB/
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Fig. 2. Analysis of the APP CY domain interaction with its intracel-
lular ligands. The type I turn motifs are underlined. The minimal
regions of APP involved in the interaction with Fe65, X11, Go and
APP-BP1 are reported in the lower part of the ¢gure. For the origi-
nal results see refs. [19,27,30,40].
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PID domains of Shc and IRS-1, whose binding to the EGFR
or to the insulin receptor is strictly dependent on the phos-
phorylation of the tyrosine residue of the NPXY motif [41]
and on the presence of hydrophobic residues in position 35 or
36 to 38 with respect to the phosphorylated tyrosine [42].
Comparing these data with those obtained with Fe65 and
X11, it is evident that the PID/PTB domains of these two
proteins have a signi¢cantly di¡erent peptide speci¢city com-
pared to Shc and IRS1. In fact, although the NPXY motif is
present in the APP cytodomain, the Fe65- and X11-APP in-
teractions are independent from the tyrosine phosphorylation,
and in addition the tyrosine of the NPTY motif can be
changed into alanine without a¡ecting the binding.
The other turn, TPEE, is included in the putative recogni-
tion sites of Fe65 and Go, but a detailed analysis of this motif
is necessary to evaluate its role for the binding of the two
proteins.
The regulation of the binding of all these proteins to APP
could be based on several mechanisms: (i) phosphorylation of
the various partners; (ii) their di¡erent intracellular localiza-
tion; (iii) regulation of their amounts; (iv) conformational
changes preventing (or favoring) the binding.
Phosphorylation of APP was studied in detail : it is phos-
phorylated in vitro at three sites in the cytodomain by protein
kinase C, calcium/calmodulin-dependent kinase and by cdc2
kinase [43], and in vivo by cdc2 kinase and other unidenti¢ed
kinases [43,44]. The possible e¡ect of these phosphorylation
events on the binding of ligands to the APP cytodomain was
not studied; however, Thr668, which is phosphorylated by
cdc2 kinase, both in vitro and in vivo, belongs to the above
mentioned turn TPEE, which could be involved in the inter-
action with either Fe65 or Go. Very little is known about the
possible phosphorylation of the other proteins involved in the
network. We recently demonstrated that Fe65 is phosphoryl-
ated [45]; this phosphorylation takes place in a region of the
protein that does not seem to be involved in the interaction
with APP.
Similarly to phosphorylation, the intracellular localization
of APP was analyzed in great detail. Summarizing a huge
amount of results, APP was found at plasma membrane, in
the endosomal-lysosomal compartment and in the Golgi net-
work. Therefore it is evident that this protein undergoes com-
plex intracellular tra⁄cking, which could have an important
role in the targeting of APP to speci¢c processing machineries.
The NPTY motif present in the cytosolic domain of APP is
identical to the signals responsible for clathrin-coated pit in-
ternalization, and in fact cell-surface APP is targeted to the
lysosomal compartment [46]. A signi¢cant fraction of APP
has been detected in neuronal cells in vesicular elements
spread in all the cell and on the surface of dendrites and axons
[47,48]. The axonal sorting of APP is independent from pos-
sible signals present in its cytoplasmic domain [49], whereas
sorting of APP in MDCK cells to the basolateral surface is
directed by a signal present in the cytodomain and including
Tyr653 [50]. These results exclude the possibility that either
Fe65 or X11 could have any role in this pathway, because
mutation of Tyr653 has no e¡ect on the binding of Fe65 and
X11 [27] and because the deletion of the C-terminal 32 resi-
dues of APP, that contain the binding site of these two pro-
teins, does not a¡ect signi¢cantly the proper sorting of APP
[50]. Therefore, it must be hypothesized that (an)other pro-
tein(s) interact(s) with APP at the region including Tyr653 and
is responsible for the regulation of its basolateral sorting in
MDCK cells.
6. Interaction of Fe65 with other proteins
Fe65 possesses two other protein-protein interaction do-
mains, distinct from that interacting with APP: a WW do-
main and a second PID/PTB domain (PID1).
At least ¢ve putative polypeptides from mouse brain lysates
have been puri¢ed by a⁄nity chromatography with a GST-
Fe65 fusion protein containing the WW domain; two of them
have been identi¢ed by co-immunoprecipitation experiments
as two isoforms of Mena, the mammalian homolog of the
Drosophila enabled protein [51].
Mena cDNA has been isolated by the screening of mouse
libraries using the Drosophila Enabled (Ena) as a probe [52]; it
belongs to the Ena/VASP family of proteins; the main feature
of this family, comprising four members, Ena, Mena, Evl and
VASP, concerns the presence of two conserved N- and C-
terminal Ena/VASP homology domains (EVH1 and EVH2,
respectively) spaced by a central proline-rich region. Mena
and VASP share several features: they are strongly enriched
in focal contacts and in the cellular sites where active actin
remodelling occurs, such as lamellipodia; both proteins are
phosphorylated and a neuron-speci¢c isoform of Mena, de-
rived from the presence of an alternatively spliced exon, is
phosphorylated at tyrosine residue(s) [52]. Mena, as well as
VASP, is involved in many protein-protein interactions; its N-
terminal EVH1 domain interacts with FPPPP regions present
in vinculin, zyxin and the ActA protein from the intracellular
pathogen Listeria monocytogenes ; furthermore, Mena binds to
pro¢lin, a protein interacting with G-actin, through the poly-
proline region [52]. The Mena-Fe65 complex involves PPLP
sequences present in the central, proline-rich region of Mena,
as determined by ¢lter binding and competition assays [51]. In
order to elucidate the functional relevance of Mena-Fe65 in-
teraction, it is very important to evaluate the potential in-
volvement of such proteins in multiprotein complexes; if
this is the case, Fe65 could act as an adapter protein trans-
ducing so far unde¢ned stimuli involving APP to the cytoskel-
eton dynamics through Mena and downstream regulators of
the actin polymerization, such as pro¢lin. Furthermore, it has
been shown that Mena strongly interacts with zyxin, which in
turn is tightly related to focal contacts [52]. These observa-
tions are in agreement with the co-localization of APP in
primary neurons with adhesion plaque components, that
was suggested to support a role for the APP extracellular
domain in mediating cell-matrix interaction [53].
The presence of Mena in the growth cones of P19 cells
induced to di¡erentiate to neurons by retinoic acid and the
existence of a tyrosine-phosphorylated, neuron-speci¢c iso-
form of Mena starting to appear, in mouse development, in
the period of active neurite outgrowth, is suggestive of a po-
tential involvement of Mena in neurite development; further-
more, ectopic expression of the neural isoform of Mena in
¢broblasts induces the formation of F-actin-rich outgrowths
resembling the micro¢lament-based extension of ¢lopodia oc-
curring during migration of the axonal growth cone [52]. The
support for a possible relevance of the APP-Fe65-Mena sys-
tem in the axonal development comes from the analysis of the
neuronal phenotype of mice homozygous for an APP-null
mutation, whose hippocampal neurons are less viable in pri-
FEBS 20703 27-8-98
T. Russo et al./FEBS Letters 434 (1998) 1^74
mary cultures, present reduced ability to develop neurites and
show reduced branching compared to wild-type neurons [54] ;
such phenotypes are in agreement with the suggested function
of Mena in the axonal development.
Given the expected localization of APP-Fe65 and Mena-
Fe65 complexes it was surprising to ¢nd that the ligand of
the third protein-protein interaction domain of Fe65, the
PID1 element, is an already known transcription factor,
named CP2/LSF/LBP-1 [45]. Biochemical and cell fractiona-
tion analyses have demonstrated that speci¢c isoforms of
CP2/LSF/LBP1 are present, as expected, in the nuclear frac-
tion, but also in the cytosolic membrane fraction [45]. The
shorter CP2/LSF/LBP1 isoform (LSF-ID), probably derived
from an alternative splicing and missing a 50-amino acid re-
gion encoding part of the oligomerization/DNA binding do-
main, is enriched in the cytosolic membrane fraction, while
the full-length protein is mostly nuclear. On the other hand,
even though most of the cellular Fe65 is associated with the
cytosolic fraction, a discrete amount of the slowest-migrating,
phosphorylated Fe65 isoforms have been found in nuclear
fraction. In any case, the complexes between Fe65 and all
the forms of CP2/LSF/LBP1 have been found in both nuclear
and cytosolic membrane fractions [45].
The observed distribution of the two proteins and of the
cognate complexes supports the hypothesis that Fe65 is in-
volved in a regulatory mechanism underlying the targeting
of the transcription factor to the nucleus. Among the possible
cellular targets of CP2/LSF/LBP1, two gene promoters that
are activated in early phases following mitogenic stimuli, the
c-fos and the ODC promoters, respectively, possess putative
DNA binding sites for CP2/LSF/LBP1. Interestingly, the
DNA binding activity of CP2/LSF/LBP1 is also regulated
by its phosphorylation in the earliest phases following mito-
genic stimuli [55]; furthermore, preliminary data indicate that
Fe65 itself is actively phosphorylated early following serum
stimulation of serum-starved cells (unpublished results). Con-
sidering that the phosphorylated forms of Fe65 seem to accu-
mulate preferentially in the nuclear fraction, it is likely that
the phosphorylation of CP2/LSF/LBP1 and Fe65 in the early
phases of the cell cycle regulates the translocation of Fe65-
CP2/LSF/LBP1 complexes to the nuclear fraction. Another
possibility to consider concerns the direct involvement of
Fe65 in the formation of DNA-protein complexes with CP2/
LSF/LBP1; since the CP2/LSF/LBP1 protein region involved
in the interaction with Fe65 is located downstream the dimer-
ization/DNA binding domain, the possibility of interacting
with the DNA by a CP2/LSF/LBP1-Fe65 complex cannot
be excluded. Interaction with Fe65, instead, involves the
C-terminal region of the protein, in which the putative, glu-
tamine-rich transactivation domain of CP2/LSF/LBP1 is con-
tained [56]. In this case, Fe65 could a¡ect the transactivating
properties of CP2/LSF/LBP1 by masking its transactivation
domain. Moreover, the possibility that Fe65 itself could ac-
tivate the transcription cannot be excluded. In fact, it has been
shown that a region of Fe65 possesses intrinsic transactivating
properties when fused to the yeast GAL4 DNA binding do-
main, being able to transactivate a CAT reporter gene con-
trolled by GAL4 cis-elements in co-transfection experiments
[15].
The distribution of Fe65 between the nuclear compartment
and the other districts of the cell must be studied in more
detail. The results available at this moment indicate that the
targeting of Fe65 to the nuclear fraction is regulated, and a
phosphorylated region £anking the N-terminal side of the
WW domain is necessary for this regulation [45]. It is not
yet clear whether Fe65 is located within the nucleus or at
perinuclear membranes; this last possibility deserves particu-
lar attention. In fact, a localization of PS1 and PS2 at the
nuclear membrane in association with kinetochores and cen-
trosomes was recently demonstrated [57]. This interesting ob-
servation supports the hypothesis that Alzheimer’s mutant
presenilins could generate chromosomal missegregation and/
or could alter gene expression giving rise to the AD phenotype
[57]. Given the existence of APP-PS complexes in living cells
[58,59], it seems conceivable to postulate that Fe65 could be
associated, together with APP and PS, to the inner nuclear
membrane.
7. Perspectives
Fig. 3 summarizes the scenario that can be outlined around
the APP cytodomain. At least three molecular machineries
have been suggested to compete for this small domain. First,
it can be hypothesized that a Go protein-centered machinery
transduces unknown extracellular or intraluminal signals to
the cytoplasm and to the nucleus; several results suggest
that this machinery controls cell apoptosis and could be in-
volved in the pathological phenotypes associated with FAD
mutations. Second, X11 protein has the characteristics of an
adaptor protein, whose binding to APP is expected to be
alternative to that of Fe65. It could link APP to other pro-
teins by its PDZ domains. The ligands of these domains are
not known, but it could be hypothesized that they are in-
volved in the regulation of APP processing. Lastly, Fe65
seems to be the structural element connecting APP to the
cytoskeleton through Mena, which in turn interacts with pro-
¢lin-actin complexes or to zyxin or to vinculin. This connec-
tion could represent the molecular basis of the suggested role
for APP to regulate axonal targeting through cell-matrix and
cell-cell interactions. On the other hand, Fe65-CP2/LSF/LBP1
complexes suggested that the APP network is also able to
a¡ect gene regulation; this could play an important role in
the neuronal molecular di¡erentiation related to synaptic plas-
ticity and involved in the learning process. This complex sce-
nario probably has further degrees of complexity, given the
¢nding that another protein, APP-BP1, is able to interact with
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Fig. 3. Schematic representation of the protein-protein interaction
network centered to the APP cytodomain. Some possible down-
stream targets of the network are indicated.
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APP, and considering that the existence cannot be excluded of
other not yet identi¢ed ligands of the juxta-membrane seg-
ment of the APP cytodomain, which could be involved in
the demonstrated baso-lateral sorting of APP in MDCK cells.
The ¢nding that APP and PS interact could help to ¢nd a
coherent model to explain how the dysfunction of two appar-
ently unrelated proteins generates a single pathological phe-
notype. The CY domain of APP does not seem to be involved
in the interaction with PS1 and PS2 [58] ; therefore, the de-
scribed protein-protein network is not the bridge between
APP and PS. However, an indirect connection between pre-
senilins and the various components of the network must be
taken into account.
Future directions of the research have to be aimed at the
elucidation of the possible role of the described protein-pro-
tein interaction network in: (i) APP processing and LA gen-
eration; (ii) APP and presenilins tra⁄cking among the various
intracellular compartments; (iii) APP and presenilin involve-
ment in apoptotic process; (iv) regulation of gene expression.
In any of these ¢elds the functions of the APP-centered pro-
tein network could contribute to ¢ll the numerous gaps in the
knowledge of AD pathogenesis and also, more importantly,
could become a target for the design of therapeutic agents to
be developed in the next future.
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